Skip to content

Investors Flee Drug Giants as Zantac Cancer Trials Approach

  • Sanofi, GSK, Haleon lost $40 billion of market value in days
  • Recalled drug Zantac faces wave of product-liability suits
Shipments Of A Generic Zantac Halted After FDA Warns Of Low Level Probable Carcinogen In Zantac And Its Generic Version

Photographer: Drew Angerer/Getty Images


GSK Plc and Sanofi rose for the first time this week following a selloff triggered by investors waking up to the risk that US juries could hold the drug companies accountable for cancers allegedly caused by contaminants in a once-popular antacid. 

Shares in Britain’s GSK gained as much as 5% on Friday while the French group Sanofi rose 3.2% after both pharmaceutical giants said they would vigorously defend any claims and disputed the idea that an ingredient in the drug Zantac caused cancer.